A. D. Colevas

Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models

Jeffrey M. Albert, Carolyn Cao, Kwang Woon Kim et al. · Clinical Cancer Research · 2007 · 265 citations

Medicine, Oncology, Radiation Oncology +17

The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials

A. D. Colevas, Ann Setser · Journal of Clinical Oncology · 2004 · 111 citations

Pharmacy, Oncology, Cancer Drug Toxicity Management +15

NCCN Practice Guidelines for Head and Neck Cancers.

David G. Pfister, K.K. Ang, B. Brockstein et al. · PubMed · 2000 · 99 citations

Medicine, Neck Surgery, Oncology +14

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

Thomas J. Galloway, Lori J. Wirth, A. D. Colevas et al. · Clinical Cancer Research · 2015 · 99 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial

Timothy W. Synold, Robert J. Morgan, Edward M. Newman et al. · Journal of Clinical Oncology · 2005 · 75 citations

Medicine, Oncology, Pharmacology +17